Page last updated: 2024-11-02

oxidopamine and Dementia

oxidopamine has been researched along with Dementia in 2 studies

Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).

Dementia: An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Fan, Y1
Li, M1
Wu, C1
Wu, Y1
Han, J1
Wu, P1
Huang, Z1
Wang, Q1
Zhao, L1
Chen, D1
Zhu, M1
Lindner, MD1
Cain, CK1
Plone, MA1
Frydel, BR1
Blaney, TJ1
Emerich, DF1
Hoane, MR1

Other Studies

2 other studies available for oxidopamine and Dementia

ArticleYear
Chronic Cerebral Hypoperfusion Aggravates Parkinson's Disease Dementia-Like Symptoms and Pathology in 6-OHDA-Lesioned Rat through Interfering with Sphingolipid Metabolism.
    Oxidative medicine and cellular longevity, 2022, Volume: 2022

    Topics: Alzheimer Disease; Animals; Brain Ischemia; Dementia; Disease Models, Animal; Lipid Metabolism; Male

2022
Incomplete nigrostriatal dopaminergic cell loss and partial reductions in striatal dopamine produce akinesia, rigidity, tremor and cognitive deficits in middle-aged rats.
    Behavioural brain research, 1999, Volume: 102, Issue:1-2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Animals; Brain Mapping; Corpus Striatum; Dementia; Dopa

1999